Related Experiment Video

Updated: Dec 19, 2025

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

15.1K

Src Family Kinases as Therapeutic Targets in Advanced Solid Tumors: What We Have Learned so Far

Stefano Martellucci1,2, Letizia Clementi1, Samantha Sabetta1

  • 1Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, 67100 L'Aquila, Italy.

Cancers
|June 6, 2020
PubMed

Insights

Src Family tyrosine Kinases (SFKs) drive cancer growth and metastasis. While SFK inhibitors show promise in solid tumors, clinical application faces challenges, necessitating further research for effective cancer therapy.

Area of Science:

  • Molecular Biology
  • Oncology
  • Biochemistry

Background:

  • Src Family tyrosine Kinases (SFKs) are crucial non-receptor kinases regulating cell signaling.
  • SFKs are implicated in cell proliferation, migration, invasion, and metastasis in solid cancers.
  • SFK dysregulation is linked to tumor growth and the formation of distant metastases.

Purpose of the Study:

  • To review the molecular mechanisms of SFKs in cancer spreading and metastasis.
  • To discuss preclinical and clinical data on SFK inhibitors in solid tumors.
  • To highlight challenges and future directions for SFK-targeted therapy in solid cancers.

Main Methods:

  • Literature review of molecular mechanisms.
  • Analysis of preclinical data on SFK inhibitors.
  • Evaluation of clinical trial outcomes for SFK-targeted therapies.

Main Results:

  • SFKs play a significant role in promoting tumor growth and metastasis.
  • SFK inhibitors demonstrate efficacy in blocking cancer progression in preclinical models.
  • Clinical trials reveal unexpected complications hindering effective patient utilization of SFK inhibitors in solid tumors.

Conclusions:

  • SFKs are key drivers of cancer progression and metastasis.
  • Targeting SFKs presents a promising therapeutic strategy for solid tumors.
  • Overcoming clinical challenges is essential for the successful application of SFK inhibitors in cancer treatment.
Keywords:
Srccancer invasioncancer metastasizationcancer migrationclinical trialdasatinibepithelial-to-mesenchymal transitionsrc family tyrosine kinasestargeted therapy

More Related Videos

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

14.2K
Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

8.2K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.5K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
3.7K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.5K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.1K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.0K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
6.1K